Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(2.89)
# 1,356
Out of 5,182 analysts
110
Total ratings
51.52%
Success rate
7.07%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Neutral | n/a | $0.36 | - | 2 | Mar 23, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $4.40 | +127.27% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $135.17 | +70.16% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.88 | +112.77% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $6.89 | +59.65% | 2 | Oct 30, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $567.16 | -7.43% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $53.18 | +69.24% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $430.29 | +11.55% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $58.71 | -6.32% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $130.40 | -38.65% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.53 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $751.57 | +35.05% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $344.55 | +17.54% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $305.54 | -28.00% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $15.98 | -37.42% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $2.70 | +140.74% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $48.79 | +47.59% | 1 | Apr 13, 2023 |
Gossamer Bio
Mar 23, 2026
Downgrades: Neutral
Price Target: n/a
Current: $0.36
Upside: -
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $4.40
Upside: +127.27%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $135.17
Upside: +70.16%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.88
Upside: +112.77%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $6.89
Upside: +59.65%
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $567.16
Upside: -7.43%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $53.18
Upside: +69.24%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $430.29
Upside: +11.55%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $58.71
Upside: -6.32%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $130.40
Upside: -38.65%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $13.53
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $751.57
Upside: +35.05%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $344.55
Upside: +17.54%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $305.54
Upside: -28.00%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $15.98
Upside: -37.42%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $2.70
Upside: +140.74%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $48.79
Upside: +47.59%